Abstracts Archive - Page 143 of 2607 - ACR Meeting Abstracts

Abstract Number: 0175 • ACR Convergence 2025
Patient Satisfaction with a New Patient Video Triage Program
Adam Dore¹ and Yue Yin², ¹Allegheny Health Network, Pittsburgh, PA, ²Allegheny Health Network, Pittsburgh
Background/Purpose: To assist with lowering new rheumatology patient appointment wait times, our division initiated a New Patient Video Triage Program in 2023. In this program,…
Abstract Number: 0139 • ACR Convergence 2025
When One Isn’t Enough: Does Adding IgM Worsen the Antiphospholipid Syndrome Phenotype?
Santiago Dans Caballero¹, Massimo Radin², Chary López pedrera³, MARIA ANGELES AGUIRRE ZAMORANO⁴, Christian Merlo-Ruiz⁵, Ismael Sanchez-Pareja⁴, Irene Cecchi⁶ and Savino Sciascia⁷, ¹Reina Sofia University Hospital, Lebrija, Andalucia, Spain, ²University of Turin, Turin, Turin, Italy, ³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ⁴Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁵Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁶University of Turin, Turin, Piemonte, Italy, ⁷University of Turin, Torino, Italy
Background/Purpose: Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by the persistent presence of antiphospholipid antibodies (aPL) along with clinical manifestations such as venous…
Abstract Number: 0180 • ACR Convergence 2025
Digital Transformation in IMID Care: Results from the Implementation of IMIDOC
JOSE INIESTA-CHAMORRO¹, Marta Novella-Navarro², Diego Benavent³, HELENA BORREL-PAÑOS⁴, Xabier Michelena Vegas⁵, Javier Bachiller⁶, Verónica García García⁷, ESTHER ESPARTAL⁴, LETICIA LOJO-OLIVEIRA⁸, Enrique Calvo-Aranda⁹, José Rodríguez gago¹⁰, Gema Bonilla¹¹, Irene Monjo Henry², Victoria Navarro-Compan¹², Jaime Arroyo¹⁰, Eugenio de Miguel², Mariana Díaz-Almirón¹³, cARMEN ALEGRE¹⁰, ENRIQUE J GÓMEZ¹⁴ and Chamaida Plasencia-Rodríguez², ¹¹Biomedical Engineering and Telemedicine Centre, ETSIT, Center for Biomedical Technology, Universidad Politéctica de Madrid, TELEMEDICINE, MADRID, ²Hospital Universitario La Paz, Madrid, Spain, ³Hospital Universitari de Bellvitge, Madrid, Spain, ⁴⁴HOSPITAL UNIVERSITARIO VALL D´HEBRON, RHEUMATOLOGY, BARCELONA, Spain,, BARCELONA, ⁵Hospital Universitari Vall Hebron, Barcelona, Spain, ⁶Hospital Ramon y Cajal, Madrid, Madrid, Spain, ⁷Ramón y Cajal University Hospital, MADRID, Spain, ⁸Hospital Universitario Infanta Leonor, Madrid, Spain, ⁹Department of Rheumatology, Hospital Universitario Infanta Leonor / Universidad Complutense de Madrid, Madrid, Spain, madrid, ¹⁰Hospital Universitario La Paz, MADRID, ¹¹Hospital Universitario La Paz, Rheumatology, Madrid, Madrid, Spain, ¹²Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ¹³LIMA, Advanced Medical Informatics Lab, La Paz Research Institute, IdiPAZ, Madrid, Spain, ¹⁴¹Biomedical Engineering and Telemedicine Centre, ETSIT, Center for Biomedical Technology, Universidad Politéctica de Madrid, TELEMEDICINE, MADRID, Spain,, MADRID
Background/Purpose: Rheumatoid arthritis (RA) and spondyloarthritis (SpA) are immune-mediated inflammatory diseases (IMIDs) characterized by joint and spinal inflammation, leading to functional impairment. Their management requires…
Abstract Number: 0200 • ACR Convergence 2025
Severe infections and malignancies in patients with cranial and extracranial giant cell arteritis treated with tocilizumab. National multicenter study of 471 patients of clinical practice
Adrian Martin-Gutierrez¹, Javier Loricera², Vicente Aldasoro Cáceres³, Olga Maiz⁴, Eugenio de Miguel⁵, Eva Galíndez Agirregoikoa⁶, Ivan Ferraz Amaro⁷, Santos Castañeda⁸ and Ricardo Blanco⁹, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Renedo de Piélagos, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Hospital Universitario de Navarra, Pamplona, Spain, ⁴Hospital Universitario de Donosti, Donostia, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ⁷Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁸Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ⁹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Infections and malignancies are two of the most feared side effects of biologic therapies. Giant cell arteritis (GCA) is a vasculitis which affects older…
Abstract Number: 0239 • ACR Convergence 2025
Safety of Rilzabrutinib, a BTK Inhibitor, in Adult Patients with IgG4-related disease (IgG4-RD) in a 52-week Phase 2 Open-label Study
Alireza Meysami¹, Mollie Carruthers², John Stone³, Fernando Martinez-Valle⁴, nicolas schleinitz⁵, Daniela Ghetie⁶, Robert Spiera⁷, Jeea Choi⁸, Leda Mannent⁹ and Owen Hagino⁸, ¹Henry Ford Health, Detroit, MI, ²Vancouver General Hospital, Vancouver, BC, Canada, ³Massachusetts General Hospital , Harvard Medical School, Concord, MA, ⁴Vall d’Hebron Hospital, Barcelona, Spain, ⁵Aix Marseille university, AP-HM, Marseille, France, ⁶Oregon Health and Science University, Portland, OR, ⁷Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁸Sanofi, Morristown, NJ, ⁹Sanofi, Gentilly, France
Background/Purpose: IgG4- related disease (IgG4-RD) is a chronic, progressive, immune-mediated fibrotic disease with limited treatment options. Rilzabrutinib is an orally available, reversible, inhibitor of Bruton's…
Abstract Number: 0150 • ACR Convergence 2025
Mortality in Anca-associated Vasculitis
Fabricio Benavides Villanueva¹, Vanesa Calvo-Río², Diana Prieto-Peña³, Monica Renuncio-García⁴, Adrian Martin-Gutierrez⁵, Amparo Sanchez-Lopez⁶, Claudia Poo-fernandez⁷, Clara Escagedo-Cagigas⁸, maria Rodríguez-Vidriales⁸ and Ricardo Blanco², ¹Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Immunopathology Group,Santander, Spain, Santander, Spain, ²Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, ⁴Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain, ⁵Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Renedo de Piélagos, Spain, ⁶Division of Dermatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain, ⁷Division of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain, ⁸Division of Nephrology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Cantabria, Spain
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), include Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), and Eosinophilic Granulomatosis with Polyangiitis (EGPA). Mortality rates are scare,…
Abstract Number: 0247 • ACR Convergence 2025
Use of Nintedanib in Patients with Progressive Pulmonary Fibrosis
Elizabeth Volkmann¹, Steven Nathan², Karen Coeytaux³, Yanni Fan⁴, Jill Curran³, Haikun Bao³, Kamila Sroka-Saidi⁵, Ann Chauffe⁶ and Jeffrey J Swigris⁷, ¹Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA, ²Inova Advanced Lung Disease and Transplant Program, Falls Church, VA, USA, Falls Church, ³Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, ⁴Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, CT, ⁵Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁶Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Newberry, FL, ⁷Center for Interstitial Lung Disease, Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO, USA, Denver
Background/Purpose: Nintedanib was approved in the US for the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (progressive pulmonary fibrosis [PPF])…
Abstract Number: 0098 • ACR Convergence 2025
The Deubiquitinase TRABID is a Regulator of Osteogenesis and Inflammation in Spondyloarthritis:
Archita Srinath¹, Sungsin Jo², Daniele Mauro³, Mariia Korshko⁴, Mansi Aparnathi⁵, Shaghayegh Foroozan Boroojeni⁶, Tae-Hwan Kim⁷, Francesco Ciccia⁸ and Nigil Haroon⁹, ¹University of Toronto, Toronto, ON, Canada, ²Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ³University of Campania, Italy, Naples, Italy, ⁴UHN, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ⁶University Health Network/University of Toronto, Toronto, ON, Canada, ⁷Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁸University of Campania, Naples, Italy, ⁹Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Axial Spondyloarthritis (AxSpA) is characterized by both inflammation and new bone formation. Current therapeutic targets aim to control inflammation, however over 40% of patients…
Abstract Number: 0122 • ACR Convergence 2025
The role of low profile antiphospholipid antibodies and adverse pregnancy outcomes.
Eugenia Chock¹, Tong Wang², Areeka Memon³, Zeyan Liew⁴ and Pengfei Guo⁴, ¹Yale School of Medicine, New Haven, CT, ²Yale School of Public Health, New Haven, ³Yale New Haven Health, New Haven, CT, ⁴Yale Center for Perinatal, Pediatric and Environmental Epidemiology, New Haven
Background/Purpose: Presence of high titer antiphospholipid antibodies (aPLs) confer adverse pregnancy outcomes (APOs). Patients with low titer aPLs often receive conflicting counseling on treatment, many…
Abstract Number: 0246 • ACR Convergence 2025
Fracture Risk in Intestinal Autoimmune-mediated Diseases Patients: Clinical Insights from REMS
Marco Di Paola¹, Fiorella Anna Lombardi¹, Edmund J MacLaughlin², Maurizio Muratore³, Kathleen Methric⁴, Gianmarco Del Vecchio⁵, Giusy Peluso⁶, Chiara Stomaci⁷, Roberto Franchini¹, Francesco Conversano¹, Paola Pisani¹ and Sergio Casciaro¹, ¹Institute of Clinical Physiology, National Research Council, Lecce, Puglia, Italy, ²Rheumatology Associates of Delmarva and BoneVue Diagnostics, Easton, MD, ³ASL- LE, "Vito Fazzi" Hospital, Lecce, Puglia, Italy, ⁴BoneVue Diagnostics, Catonsville, MD, ⁵Department of Research and Development, Echolight S.p.a., Lecce, Puglia, Italy, ⁶Department of Innovative Engineering, University of Salento, Lecce, Puglia, Italy, ⁷Department of Biological and Envinronmental Sciences and Technologies, University of Salento, Lecce, Puglia, Italy
Background/Purpose: Intestinal Bowel Diseases (IBD), including Crohn’s (ChD), and Ulcerative Colitis (UCD), along with Celiac (ClD), diseases are chronic inflammatory conditions that primarily affect the…
Abstract Number: 0167 • ACR Convergence 2025
Geographic and Demographic Patterns of Rheumatoid Arthritis in the United States: Insights from GBD 2021
Punith Chirumamilla¹, Sameer Kumar Majety², Rithish Nimmagadda³, Ravi Medarametla⁴, Priya Sunkara⁵, Pranathi Bandarupalli⁶, Anjani Mahesh Kumar Cherukuri⁷ and Himaja Anne⁸, ¹Baptist Memorial Hospital North Mississippi, Oxford, MS, ²School of Medicine, Xiamen University, China, Kakinada, Andhra Pradesh, India, ³One Brooklyn Health, New York, NY, ⁴Mamata Medical College, Guntur, Andhra Pradesh, India, ⁵White River Health, Batesville, AZ, ⁶Mercy St Vincent Medical Center, Toledo, OH, ⁷Guntur Medical College, Guntur, Andhra Pradesh, India, ⁸Hind Institute of Medical Sciences, Sitapur, Uttar Pradesh, India
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune, systemic disease with a rising U.S. healthcare burden. Utilizing Global Burden of Disease (GBD) 2021 estimates, we analyzed…
Abstract Number: 0258 • ACR Convergence 2025
Performance characteristics of anti-Collagen II antibodies for diagnosing inflammatory and non-inflammatory diseases: a systematic review and meta-analysis
Karyssa Stonick¹, Marcela ferrada², Alice Fike³, Kaitlin Quinn³, Benjamin Turturice³, Casey Stein⁴ and Peter Grayson⁵, ¹National Insitute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ²University of Maryland, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁴NIAMS, NIH, Chevy Chase, MD, ⁵National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: Anti-collagen II (Col2) antibodies have been clinically and experimentally associated with relapsing polychondritis (RP), rheumatoid arthritis (RA), and other diseases. Whether anti-Col2 antibodies are…
Abstract Number: 0227 • ACR Convergence 2025
Malignancy Screening of Dermatomyositis Patients in the Penn State Registry of Inflammatory Myopathies (PRIMO)
Katrina Gonzales¹, William DeKryger², Deepika Pugalenthi Saravanan², Esha Tulsian², Peri Newman³, Jacob Colello², Galen Foulke⁴ and Nancy Olsen⁵, ¹Penn State College of Medicine, Hummelstown, PA, ²Penn State College of Medicine, Hershey, PA, ³Penn State Health/ Penn State College of Medicine, Hershey, PA, ⁴Penn State Health, Hershey, PA, ⁵Penn State University/Milton S Hershey, Hershey, PA
Background/Purpose: Dermatomyositis (DM) is an immune-mediated myopathy characterized by muscle weakness and skin rash that carries an elevated risk of associated malignancy within 5 years…
Abstract Number: 0253 • ACR Convergence 2025
Ophthalmology Screening for Asymptomatic Uveitis in Sarcoidosis Patients: A Single-Center Investigation
Justin Nguyen¹, Philip Bucur², Sai Patel², Aamer Syed², Thomas Iden³, Jessica McLaughlin², Neha Gupta², Jordana Kron², Kelly Gwathmey², Ryan Canissario², Vaishali Patel² and Huzaefah Syed², ¹Virginia Commonwealth University Medial Center, Richmond, VA, ²Virginia Commonwealth University Medical Center, Richmond, VA, ³Virginia Commonwealth University Medical Center, Richmond
Background/Purpose: Asymptomatic ocular involvement must be considered in any patient with sarcoidosis. If left untreated, severe complications, including vision loss, can occur. As a result,…
Abstract Number: 0267 • ACR Convergence 2025
Pharmacosurvellience study of FDA Adverse Event Reporting System (FAERS) events of Secukinumab and Guselkumab
NUR BARLAS¹, Sait Barlas¹ and Emre Adalier², ¹Florida State University College of Medicine, Cape Coral, ²University of Pavia School of Medicine & Surgery, Pavia, Italy
Background/Purpose: Interleukin-17 (IL-17) and interleukin-23 (IL-23) inhibitors have revolutionized treatment for psoriatic arthritis, axial spondyloarthritis, and moderate-to-severe plaque psoriasis. IL-17 inhibitors block the pro-inflammatory cytokine…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].